Myo T. Naung

Myo T. Naung

Auto-generated profile, based on publicly available information

Myo T. Naung

Centre for Innovation in Infectious Diseases and Immunology Research (CIIDIR), Institute for Mental and Physical Health and Clinical Translation and School of Medicine, Deakin University, Geelong, VIC, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ZSZalak Shah
Zalak Shah
MNMyo T. Naung
Myo T. Naung
KMKara A. Moser
Kara A. Moser
MAMatthew Adams
Matthew Adams
ABAndrea Buchwald
Andrea Buchwald
STShannon Takala-Harrison
Shannon Takala-Harrison
Individuals acquire immunity to clinical malaria after repeatedPlasmodium falciparuminfections. Immunity to disease is thought to reflect the acquisition of a repertoire of responses to multiple alleles in diverse parasite antigens. In previous studies, we identified polymorphic sites within individual antigens that are associated with parasite immune evasion by examining antigen allele dynamics in individuals followed longitudinally. Here we expand this approach by analyzing genome-wide polymorphisms using whole genome sequence data from 140 parasite isolates representing malaria cases from a longitudinal study in Malawi and identify 25 genes that encode possible targets of naturally acquired immunity that should be validated immunologically and further characterized for their potential as vaccine candidates.

23 October 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
ABAlison Paolo N Bareng
Alison Paolo N Bareng
MNMyo T Naung
Myo T Naung
EMEli Martin
Eli Martin
SMSomya Mehra
Somya Mehra
JMJacob E Munro
Jacob E Munro
ABAlyssa E Barry
Alyssa E Barry
Background: Knowledge of the genetic diversity of Plasmodium vivax antigen vaccine candidates can offer valuable insights into antigens targeted by host immunity and their utility as vaccine candidates. We previously catalogued the genetic diversity of DBP, MSP1, and members of the RBP family. Here we report the diversity of 14 additional P vivax vaccine candidates to identify polymorphic domains and immune selection, to guide selection of alleles for vaccine development. Methods: A total of 289 of 353 publicly available P vivax whole genome sequences from Asia, the Americas, and Oceania passed a stringent variant-calling pipeline. Measures of diversity and balancing selection were calculated both across linear gene sequences and 3-dimensional (3D) proteins. Results: The blood-stage antigens AMA1, CyRPA, RBP1a, and P41 exhibited high genetic diversity and signatures of balancing selection on both linear and 3D structures. These signatures were consistent across all endemic regions, suggesting that these polymorphic loci are under immune selection. In contrast, CSP, TRAP, MSP4, MSP9, MSP10, GAMA, S12, ARP, S25, and S28 antigens showed low to intermediate genetic diversity and variable patterns among countries. Haplotype networks identified common variants that may represent antigenically distinct clusters. Importantly, sequences from the vaccine strain Sal-1 have extremely low global frequencies. Conclusions: AMA1, CyRPA, RBP1a, and P41 are under strong immune selection, while other antigens show limited diversity. Current vaccine formulations based on Sal-1 may have limited efficacy. Our results provide a framework for vaccine developers to select more common variants.

19 May 2026 in The Lancet Microbe
Verified
Journal Article
Open access
ABAlison Paolo N Bareng
Alison Paolo N Bareng
KWKenneth W Wu
Kenneth W Wu
ETEizo Takashima
Eizo Takashima
DADionne C Argyropoulos
Dionne C Argyropoulos
LSLauren Smith
Lauren Smith
RLRhea Longley
Rhea Longley
Plasmodium vivax poses a major obstacle to malaria elimination because this parasite can lie dormant in the liver for weeks to months before reactivating and causing a relapse of infection. These dormant forms (hypnozoites) cannot be detected using standard diagnostics, but P vivax exposure in the previous 9 months and, by proxy, hypnozoite carriage, can be inferred using serological markers. In this study, we aimed to examine how genetic variation in P vivax affects the utility of these markers and whether redesigned antigens could improve performance. In this observational diagnostic accuracy study, we analysed global P vivax genetic data to assess variation in leading serological markers (n=14). Accordingly, we expressed new haplotypes that better reflect global sequence diversity for eight antigens, compared with the commonly used reference strain (Sal-1). Antibody responses against these were tested using samples from cohorts in Brazil and Thailand, with magnitude assessed in relation to how recently participants had a qPCR-detectable blood-stage P vivax infection. We compared the ability of the haplotypes versus the reference to correctly identify individuals infected within the previous 9 months. Extensive global genetic diversity was identified in two P vivax antigens, MSP5 (π=14·8 × 10-3) and DBPII (π=7·7 × 10-3). Several antigens had large numbers of circulating haplotypes, with the percentage with similar sequence identity to the reference Sal-1 ranging from 0·4% (MSP5) to 99% (S16). Samples for immune analysis were previously collected between April 2013 and June 2014, with 774 and 923 participants included in the current analysis from Thailand and Brazil, respectively. Two antigens showed strong differences in immunogenicity by region and construct (RBP2a and DBPII). However, for most proteins (five of eight: MSP5, RiPR, PTEX150, Pv-fam-a, and RBP2b), these differences had no significant effect on the accuracy of identifying recent exposure. Affected performance (eg, RBP2a) was overcome by adding multiple antigens into the classification model. Even highly diverse antigens can be effective serological markers. Our findings highlight the importance of testing the effect of genetic diversity and suggest practical strategies to ensure consistent performance across regions. Australian National Health and Medical Research Council.

19 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
STSwapnil Tichkule
Swapnil Tichkule
YMYoochan Myung
Yoochan Myung
MNMyo T. Naung
Myo T. Naung
BABrendan R. E. Ansell
Brendan R. E. Ansell
AGAndrew J. Guy
Andrew J. Guy
AJAaron R. Jex
Aaron R. Jex
Large-scale comparative genomics- and population genetic studies generate enormous amounts of polymorphism data in the form of DNA variants. Ultimately, the goal of many of these studies is to associate genetic variants to phenotypes or fitness. We introduce VIVID, an interactive, user-friendly web application that integrates a wide range of approaches for encoding genotypic to phenotypic information in any organism or disease, from an individual or population, in three-dimensional (3D) space. It allows mutation mapping and annotation, calculation of interactions and conservation scores, prediction of harmful effects, analysis of diversity and selection, and 3-dimensional (3D) visualisation of genotypic information encoded in Variant Call Format (VCF) on AlphaFold2 protein models. VIVID enables the rapid assessment of genes of interest in the study of adaptive evolution and the genetic load, and it helps prioritising targets for experimental validation. We demonstrate the utility of VIVID by exploring the evolutionary genetics of the parasitic protist Plasmodium falciparum , revealing geographic variation in the signature of balancing selection in potential targets of functional antibodies.

9 May 2026 in bioRxiv
Verified
Preprint
Open access
XXXiao Xiao
Xiao Xiao
QZQingmiao Zhou
Qingmiao Zhou
DMDanushka F. Marapana
Danushka F. Marapana
TMThomas C McLean
Thomas C McLean
RCRainbow W. B. Chan
Rainbow W. B. Chan
SSStephen W. Scally
Stephen W. Scally
Plasmodium falciparum causes the majority of severe malaria, and merozoite invasion of erythrocytes is a vulnerable, antibody‑accessible step of the blood‑stage cycle. PfRipr is an essential component of the PCRCR invasion complex, yet the structural basis for antibody‑mediated neutralisation remains unclear. Here, we map inhibitory and non‑inhibitory epitopes across PfRipr and show that all potent inhibitors localise to the tail region (EGF6-8). Crystal structures reveal that inhibitory antibodies restrict the flexibility surrounding EGF7. Indeed, EGF7 buried surface area correlates strongly with inhibitory potency, identifying this domain as the principal invasion inhibitory determinant. Pairwise antibody combinations revealed unexpected synergy, with non‑inhibitory mAbs potentiating anti‑Rh5 activity. Conditional deletion, sequence replacement or positional swapping of EGF6-8 abolished invasion, demonstrating that both sequence and spatial arrangement are indispensable. These data define EGF7 as a conserved, functionally essential vulnerability and provide a blueprint for rational EGF6-8 immunogen design capable of eliciting P. falciparum strain‑transcending protection against blood‑stage malaria.

25 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
MSMaria Saeed
Maria Saeed
EAElizabeth H Aitken
Elizabeth H Aitken
MNMyo T Naung
Myo T Naung
CBCaitlin Bourke
Caitlin Bourke
KWKenneth W Wu
Kenneth W Wu
SRStephen J Rogerson
Stephen J Rogerson
Background: Susceptibility to malaria can be influenced by host genetic factors, including immune response genes. Antibodies against Plasmodium antigens are known to play an important role in protection from clinical disease. Polymorphisms in these antibodies may result in different functional properties that could provide protection from malaria. Methods: Immunoglobulin G1 (IgG1) and IgG3 alleles and IgG3 hinge region were investigated by polymerase chain reaction (PCR) and Sanger sequencing in a longitudinal cohort of children aged 1-3 years (N=203) from East Sepik region of Papua New Guinea (PNG). Linear regression was used to investigate associations between immunoglobulin alleles and Plasmodium infections. Results: Seventy-eight percent of the children were either heterozygous (n=82, 40%) or homozygous (n=77, 38%) for IGHG3*30 (G3m29), a novel IgG3 allele. G3m29 has a long hinge region of 4 exons. Significantly fewer Plasmodium spp. infections were observed in children with the IGHG3*30 allele compared to children without the allele (β= -1.736, 95% CI [-3.39, -0.079], p=0.038). This effect was most noticeable for Plasmodium vivax asymptomatic infections as IGHG3*30 carriers had on average one fewer infection in the 18-month follow-up period as compared to non-IGHG3*30 allele carriers (β= -1.06; 95% CI [-2.01, -0.12], p=0.028). Additionally, IGHG3*30 allele carriers had significantly lower levels of IgG to P. vivax vaccine candidate proteins compared to non-IGHG3*30 allele carriers. Conclusions: The IGHG3*30 allele is highly prevalent in the East Sepik region and is associated with fewer Plasmodium spp. infections.